Preliminary Final Report
Filed with ASX · · 42 pages · English
$ No dividends have been paid or declared by the company for the current financial year. No dividends were paid for the previous financial year. Explanation of results The reported after tax loss of $8,384,465 is after fully expensing the company’s research and development expenditure of $1,367,054 incurred during the year. The company has engaged a specialised R&D Tax consultant to review the res
Earlier from Immuron
- Voluntary Suspension
- Pause in Trading
- IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
- Immuron SARS-CoV-2 Research Agreement with Monash University
- Immuron Receives AUD $358,280 R&D Tax Concession Refund
Later from Immuron
- Immuron planned Acquisition of R&D Vaccine Company
- Reinstatement to Official Quotation
- IMM124E Demonstrates Antiviral T-Cell Immunity
- US DoD Naval Medical Research Center Clinical Update
- US DoD Travelan Clinical Update
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron